Xellia Found To Infringe Merck Anti-Fungal Med Patent
Xellia Pharmaceuticals ApS' generic version of the anti-fungal medication Cancidas infringes on one of the patents held by Merck Sharp & Dohme Corp., a Delaware federal judge ruled on Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article